TY  - CHAP
AU  - Andrey Momot
AU  - Irina Taranenko
AU  - Lyudmila Tsyvkina
AU  - Nadezhda
Semenova
AU  - Irina Molchanova
ED  - Ozcan Basaran
ED  - Murat Biteker
Y1  - 2016-09-08
PY  - 2016
T1  - The Risk Factors of Thrombogenic, Thrombophilia, and the Principle for Heparin Prophylaxis in Personalized Medicine
N2  - The available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a  substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase III trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists.
BT  - Anticoagulation Therapy
SP  - Ch. 3
UR  - https://doi.org/10.5772/64118
DO  - 10.5772/64118
SN  - 978-953-51-2667-6
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-25
ER  -